SHISA3 and neoplasm: The association between SHISA3 promoter methylation status and the clinicopathological parameters of the LSCC patients, including age, gender, smoking behavior, histological grade, clinical stage, tumor stage, and lymph node metastasis, was assessed (Table 2).